Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001244777 | SCV001418021 | likely benign | Spastic paraplegia | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Paris Brain Institute, |
RCV001391464 | SCV001451238 | pathogenic | Hereditary spastic paraplegia 10 | criteria provided, single submitter | clinical testing | ||
Prevention |
RCV004738216 | SCV005350973 | uncertain significance | KIF5A-related disorder | 2024-01-31 | no assertion criteria provided | clinical testing | The KIF5A c.2147G>A variant is predicted to result in the amino acid substitution p.Arg716Gln. This variant has been reported in two individuals with amyotrophic lateral sclerosis (Nakamura et al. 2021. PubMed ID: 32888732). This variant is reported in 0.0085% of alleles in individuals of Latino descent in gnomAD. A different missense change impacting the same amino acid (p.Arg716Trp) was reported in a patient with spastic paraplegia and was interpreted as uncertain (Table 3, Iqbal et al. 2017. PubMed ID: 28362824). At this time, the clinical significance of the c.2147G>A (p.Arg716Gln) variant is uncertain due to the absence of conclusive functional and genetic evidence. |